Source: Fox News
Summary
Former U.S. Sen. Ben Sasse, who has stage 4 pancreatic cancer, is participating in a clinical trial for an experimental therapy called daraxonrasib. The drug, which targets a defective gene that triggers uncontrolled cellular growth, has shown promising results in extending the lives of patients with metastatic pancreatic cancer. In a recent interview, Sasse reported a 76% reduction in tumor volume over four months and much less pain. The drug’s manufacturer, Revolution Medicines, has shared data from a phase 3 clinical trial showing that patients on the treatment lived a median of 13 months, compared to around six months for those who continued with chemotherapy.
Our Reading
The advice sounds familiar.
Daraxonrasib’s success in clinical trials has sparked hope for a new treatment option for pancreatic cancer patients. The drug’s ability to target the RAS gene, which is often stuck in the “on” position in pancreatic cancer cells, has shown promise in slowing or shrinking tumors. While the drug is not a cure and has side effects, it has been described as “well-tolerated” compared to chemotherapy. As the medical community waits for FDA approval, daraxonrasib may become a crucial option for patients when standard chemotherapy stops working. The treatment’s limitations are a reminder that cancer is a complex and evolving disease.
It’s not the first time a new cancer treatment has been hailed as a breakthrough, only to be followed by more questions and uncertainties.
Author: Evan Null
